Supernus Pharmaceuticals Inc (SUPN)
Profitability ratios
Return on sales
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 39.28% | 29.32% | 24.52% | 19.60% | 19.71% | 32.39% | 29.06% | 30.64% | 30.55% | 24.89% | 28.68% | 29.24% | 31.72% | 37.56% | 40.83% | 46.29% | 48.95% | 61.03% | 64.04% | 65.46% |
| Operating profit margin | 12.34% | 9.06% | 4.20% | -2.27% | -0.87% | 4.85% | 3.18% | 7.31% | 6.85% | 2.75% | 8.41% | 12.77% | 15.36% | 22.56% | 26.56% | 29.43% | 34.28% | 36.85% | 37.06% | 37.83% |
| Pretax margin | 14.79% | 11.08% | 5.92% | -1.00% | 0.46% | 5.96% | 4.14% | 8.15% | 9.02% | 4.25% | 9.23% | 13.14% | 13.07% | 20.33% | 24.40% | 28.06% | 33.28% | 36.50% | 37.46% | 37.86% |
| Net profit margin | 11.16% | 9.12% | 0.83% | -2.59% | 0.22% | 4.14% | 6.76% | 7.71% | 9.02% | 5.78% | 9.30% | 12.52% | 9.54% | 15.00% | 18.17% | 20.71% | 25.05% | 27.79% | 28.24% | 28.90% |
Supernus Pharmaceuticals Inc's profitability ratios have shown fluctuations over the years. The gross profit margin declined steadily from 65.46% on March 31, 2020, to a low of 19.60% on March 31, 2024, before recovering to 39.28% by December 31, 2024. Similarly, the operating profit margin decreased from 37.83% on March 31, 2020, reaching negative figures in the following quarters, only to rebound to 12.34% by December 31, 2024. The pretax margin also followed a similar trend, decreasing from 37.86% on March 31, 2020, to a low of -1.00% on March 31, 2024, and then improving to 14.79% by December 31, 2024.
The net profit margin exhibited a downward trend as well, declining from 28.90% on March 31, 2020, to -2.59% on March 31, 2024. However, there was a notable recovery in the net profit margin, as it improved to 11.16% by December 31, 2024. These fluctuations indicate significant changes in Supernus Pharmaceuticals' profitability over the period under review.
Return on investment
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 5.97% | 4.41% | 2.02% | -1.04% | -0.41% | 2.34% | 1.58% | 2.75% | 2.71% | 1.06% | 3.07% | 4.56% | 5.09% | 7.91% | 9.31% | 10.47% | 11.55% | 11.36% | 10.40% | 12.79% |
| Return on assets (ROA) | 5.40% | 4.45% | 0.40% | -1.19% | 0.10% | 1.99% | 3.35% | 2.90% | 3.57% | 2.22% | 3.39% | 4.47% | 3.16% | 5.26% | 6.37% | 7.37% | 8.44% | 8.56% | 7.93% | 9.77% |
| Return on total capital | 8.21% | 6.32% | 3.42% | -0.65% | 0.46% | 4.22% | 3.25% | 6.50% | 7.38% | 4.14% | 8.19% | 7.53% | 7.77% | 10.98% | 13.32% | 15.20% | 17.00% | 17.70% | 17.19% | 17.70% |
| Return on equity (ROE) | 7.13% | 5.93% | 0.55% | -1.67% | 0.14% | 2.81% | 4.71% | 5.71% | 6.85% | 4.42% | 6.83% | 8.85% | 6.55% | 10.09% | 12.75% | 14.73% | 17.04% | 18.24% | 17.74% | 18.95% |
Supernus Pharmaceuticals Inc's profitability ratios have shown a declining trend over the past few years.
- Operating return on assets (Operating ROA) has decreased from 12.79% in March 2020 to -0.41% in December 2023, indicating a decrease in the company's ability to generate operating profits from its assets.
- Return on assets (ROA) also declined from 9.77% in March 2020 to 0.10% in December 2023, suggesting a decrease in overall profitability relative to its total assets.
- Return on total capital has shown a similar downward trajectory, falling from 17.70% in March 2020 to 8.21% in December 2024, indicating a lower return on investment for both equity and debt holders.
- Return on equity (ROE) has followed a similar pattern, decreasing from 18.95% in March 2020 to 7.13% in December 2024, reflecting a decline in the company's ability to generate profits for its shareholders.
Overall, the declining profitability ratios suggest that Supernus Pharmaceuticals Inc's overall profitability and efficiency in generating returns from its assets, capital, and equity have been weakening over the analyzed period.